Connect with us

Health

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) Cash/Cash Equivalents At $77.5 Million

Published

on

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) reported cash/cash equivalents of $77.5 million as of close of March 31, 2017 compared to $31 million as of end of December 31, 2016. R&D expenses for Q1 2017 came at $5.5 million, comprising stock-based compensation of $0.5 million. G&A expenses stood at $2.2 million, comprising stock-based compensation cost of $0.6 million. Net loss for Q1 2017 was $7.3 million with diluted and basic net loss of $0.60 per share.

The buzz

Zynerba considers that the current cash position is sufficient to advance five Phase III ready programs and, accepting support from the U.S. FDA to move forward, commence at least one Phase III plan and capital requirements and fund operations into 2019.

The company comes in the list of clinical-stage specialty pharma firm focused on commercializing and developing proprietary next-gen synthetic Hemp therapeutics prepared for transdermal delivery. Zynerba is advancing therapeutic candidates using its proprietary transdermal technologies that may permit sustained, controlled and consistent delivery of therapeutic levels of 2 cannabinoids: tetrahydrocannabinol and Cannabidiol.

Transdermal delivery has the prospect to mitigate adverse effects related with oral dosing. ZYN002, the firm’s Hemp gel, is the first synthetic Hemp created as a patent-protected permeation-improved gel. In June 2016, the firm commenced the Phase II STAR 1 clinical study of ‘ZYN002’ cannabinoid gel in refractory epilepsy subjects with focal seizures, the common kind of epilepsy in adults.

Last August, the Phase II STOP clinical study in people with knee pain as osteoarthritis was initiated. Also, in December 2016, Zynerba commenced the exploratory Phase II FAB-C clinical study in kids with Fragile X syndrome. The company is also advancing ZYN001, which uses a synthetically prepared pro-drug of THC. A Phase I clinical trial for ZYN001 is intended to commence in the first half of 2017.

In the last trading session, the stock price of Zynerba declined more than 2% to close the session at $18.52.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of journaltranscript.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure

BRANDS

DETAILS

SCORE

PRODUCT SITES

  • Certified Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49

9.8

30% OFF Today! “30 0FF”

  • All Natural
  • Made In U.S.A
  • Lab Tested
  • Price From $69

9.7

  • All Natural
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99

9.6

  • All Natural
  • Made In U.S.A
  • Oral Mist
  • Price From $39

9.5

BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49
SCORE

9.8

PRODUCT SITE
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Lab Tested
  • Price From $69
SCORE

9.7

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99
SCORE

9.6

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Oral Mist
  • Price From $39
SCORE

9.5

PRODUCT SITE VIEW PRODUCTS
Advertisement

Title

Uncategorized1 day ago

Best Oil Producers of 2018

Millionaires are being made by the moment in the medical marijuana industry. Venture capital firms, private equity firms, and even...

MyDx Inc MyDx Inc
Health2 weeks ago

MyDx Inc. (OTCMKTS:MYDX) Initiates Clinical Trial of Cannabis Formula for The Treatment of Chronic Low Back Pain

San Diego, CA based MyDx Inc. (OTCMKTS:MYDX) has announced the controlled trial of the cannabis formula for the treatment of...

Business2 weeks ago

Fastfunds Financial Corporation (OTCMKTS:FFFC) Is All Set to Launch Affinity Connextions Program Targeting MMJ Industry

Fastfunds Financial Corporation (OTCMKTS:FFFC) has announced the completion of all necessary formalities to introduce an Affinity Connextions Program through a...

Innovative Industrial Properties Inc Innovative Industrial Properties Inc
Business2 weeks ago

Innovative Industrial Properties, Inc (NYSE:IIPR) Unveils Exercise Of Underwriter’s Option To Purchase Common Stock Shares

Innovative Industrial Properties, Inc (NYSE:IIPR) announced recently that it has obtained the exercise of the underwriter’s option to buy additional...

Business2 weeks ago

Next Generation Management Corporation (OTCMKTS:NGMC) Updates On New Medical Marijuana System in Oregon

Nextgen Holdings, a subsidiary of the Next Generation Management Corporation (OTCMKTS:NGMC) recently updated its stockholders with the ongoing Medical Marijuana...

INDUSTRIAL HEMP2 weeks ago

Weed Inc’s (OTCMKTS:BUDZ) Performance Is Getting Higher

Weed Inc (OTCMKTS:BUDZ) has for a long time been enjoying the momentous highs for the past few months. The company’s...

INDUSTRIAL HEMP2 weeks ago

Namaste Technologies Inc (OTCMKTS:NXTTF) Signs A Share Purchase Agreement With Cannbit Ltd

Namaste Technologies Inc (OTCMKTS:NXTTF) announced recently that it signed a non-binding Letter of Intent (LOI) with Cannabit Limited where the...

INDUSTRIAL HEMP2 weeks ago

MariMed Inc. (OTCMKTS:MRMD) Plans To Expand Its Cannabis Business

MeriMed Inc. (OTCMKTS:MRMD) announced its grand plans to expand business into the emerging cannabis industry. Furthermore, the company intends to...

INDUSTRIAL HEMP2 weeks ago

Kush Bottles Inc (OTCMKTS:KSHB)’ Q1 Results For Fiscal Year 2018 Released

Leading supplier and service provider to the cannabis sector, Kush Bottles Inc (OTCMKTS:KSHB), has released financial results for 2018’s first...

INDUSTRIAL HEMP2 weeks ago

Wanderport Corp. (OTCMKTS:WDRP) Will Accept The Use Of Bitcoin In Its E-Commerce Store

Wanderport Corp. (OTCMKTS:WDRP) has made good its promise of allowing full access to the Company’s full suite of products. The...

Advertisement
Advertisement